Development of selective human DHODH inhibitors for antiviral therapy

Vol 2, 2022 - 153240
Poster
Favorite this paper
How to cite this paper?
Abstract

The human dihydroorotate dehydrogenase (hDHODH), a crucial flavin-dependent mitochondrial enzyme in the de novo pyrimidine synthesis, has been considered a promising therapeutic target to tackle tumor progression and viral infection since infectious viruses such as the SARS-CoV-2, a current global threat to public health,
require host factors including hDHODH for viral replication. Therefore, the development of selective hDHODH inhibitors as host-targeting antivirals (HTAs) may lead to effective broad-spectrum antiviral agents with minimal drug resistance induction as an alternative to Leflunomide, Teriflunomide, and Brequinar, which have known efficacy and toxicity issues. Based on the interaction profile of quinone-based molecules in the ubiquinone binding site of hDHODH, we rationalized that the heterocyclic scaffolds quinazolinone and quinoxalinone
could mimic important hydrogen-bonding interactions. Two linear synthetic routes were successfully established to obtain functionalized quinazolinones and quinazolinones which are under evaluation via enzymatic assays with hDHODH.

Share your ideas or questions with the authors!

Did you know that the greatest stimulus in scientific and cultural development is curiosity? Leave your questions or suggestions to the author!

Sign in to interact

Have a question or suggestion? Share your feedback with the authors!

Institutions
  • 1 Faculdade de Ciências Farmacêuticas de Ribeirão Preto (FCFRP), Universidade de São Paulo (USP)
  • 2 Universidade de São Paulo
Track
  • 2. Medicinal Chemistry of Synthetic Compounds
Keywords
drug design
Human DHODH
antiviral activity
Quinazolinones
Quinoxalinones